|Biotech Due Diligence||
Click to expand.
Novartis $NVS, through its Sandoz generics unit, is one of the leading biosimilars players worldwide. They also have collaborations with Momenta Pharma $MNTA around generic versions of LOVENOX (enoxaparin) and COPAXONE. Here are some highlights from their recent 1q-2013 conference call (c/o SeekingAlpha). Note there was no substantive discussion on either the enoxaparin program or their ALK inhibitor LDK378, which is covered extensively on our HSP90 Central site.
See below for recent comments from Teva Pharmaceuticals $TEVA and Baxter International $BAX relevant to Momenta Pharmaceuticals $MNTA - specifically their generic COPAXONE program for MS and their biosimilars partnership, respectively.
This post features comments from the Teva Pharmaceuticals $TEVA year-end 2012 earnings conference call that are relevant to companies covered here at BiotechDueDiligence.
As usual the discussion centers COPAXONE for multiple sclerosis, which Momenta Pharmaceutical $MNTA and partner Sandoz (Novartis $NVS) are seeking approval for a generic version of.
MNTA and biosimilars - notes from other biotech/pharma conference calls
Other blog posts related to TEVA and MNTA